Risankizumab outperforms ustekinumab in treating moderate-to-severe Crohn’s disease

Researchers compare the therapeutic efficacy of risakizumab and ustekinumab for the treatment of moderate-to-severe Crohn’s disease.

Bayer, short on cash, reaches into shareholders’ pockets

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The need-to-know this morning

February 20, 2024

Psychedelic Harm Reduction and Integration: Empowering the Psychedelic Community | Psychedelic Invest

Harm reduction and integration for people choosing to use psychedelics is important for both safety and maximization of benefits. Simply put, psychedelic harm reduction is

September 6, 2023

Free cholesterol in HDL linked to increased cardiovascular disease risk

Houston Methodist researchers have discovered that certain components of so-called “good” cholesterol — high-density lipoproteins (HDL) – may be associated with an increased prevalence of

December 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.